Blockchain Registration Transaction Record

Cybin Receives U.S. Patent for CYB003 Program Targeting Major Depressive Disorder

Cybin announces the issuance of a U.S. patent for its CYB003 program targeting major depressive disorder, underscoring its commitment to advancing mental health therapies. Learn more about the innovative research and development efforts by Cybin in the field of psychedelic-based therapeutics.

This news is crucial as it showcases the innovative work of Cybin in developing next-generation mental health therapies, addressing the unmet need for effective treatment options. The issuance of the patent underscores the company's commitment to advancing psychedelic-based treatments for mental health conditions, potentially offering hope to individuals suffering from major depressive disorder.